BioVex, Inc. Lands $40,000,000 Series F Financing Round

  • Feed Type
  • Date
    3/30/2009
  • Company Name
    BioVex, Inc.
  • Mailing Address
    34 Commerce Way Woburn, MA 01801
  • Company Description
    The Company is developing a new class of potent biologics for the treatment
    of cancer and prevention of infectious disease.
  • Website
    http://www.biovex.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $40,000,000
  • Transaction Round
    Series F
  • Proceeds Purposes
    Following the unprecedented number of durable complete remissions generated with our lead cancer product, OncoVEX GM-CSF in a Phase II study in metastatic melanoma, the funds will be used to commence a pivotal Phase III study.
  • M&A Terms
  • Venture Investor
    Forbion Capital Partners (FKA ABN)
  • Venture Investor
    Harris & Harris Group
  • Venture Investor
    New Science Ventures
  • Venture Investor
    Triathlon Medical Ventures
  • Venture Investor
    Innoven Partners
  • Venture Investor
    SEP – Scottish Equity Partners

By posting a comment, you agree to our terms and conditions.